Career developmental program (CDP) is a particulariy important activity for translational research programs. By its very nature, translational research is multidisciplinary. Because ofthe depth of knowledge required of each individual discipline, our present edicational structure seldom allows trainees to function in a multidisciplinary environment. This Career Developmental Program is designed to provide the incentive and structure necessary to bring junior investigators into multidisciplinary translational research arena. A key to success of this endeavor is the availabililty and willingness of mentors throughout the SARC institutions to meet the challenges of translational research. This Program will be chaired by Dr. Richard Goriick, Director, Sarcoma Research Laboratory, Albert Einstein College of Medicine , Division Chief, Pediatric Hematology/Oncology, The Children's Hospital at Montefiore and Vice Chairman, Department of Pediatrics, The Children's Hospital at Montefiore and will be supported by the program Administrative Director, Denise Reinke, MS, NP, Chief Operating Officer of SARC. They are joined by a committee including leaders in the fields of medical oncology (Dr. Schuetze), pediatric oncology (Dr. Mackall), tumor biology (Dr. Lev), drug resistance (Dr. Hornicek), cancer genetics (Drs. Fletcher and van de Rijn), cancer statistics (Dr. Crowley), imaging biomarkers (Dr. Schwartz) and patient advocacy (Dr. Thorton). These outstanding senior mentors, representing Albert Einstein College of Medicine, Brigham and Women's Hospital, Cancer Research and Biostatistics (CRAB), Columbia University, Massachusetts General Hospital, MD Anderson, National Cancer Institute Intramural Program, Sarcoma Foundation Of America, Stanford University School ofMedicine, University of Michigan , have enthusiastically agreed to steward the SARC Sarcoma SPORE Career Developmental Program, with responsibility for selection and support of the SPORE career development awardees.

Public Health Relevance

Providing research support and protected time for junior investigators is a general priority in translational cancer research, and particulariy so in sarcoma research, where the funding mechanisms are typically fewer than for other cancer disease types. SPORE support will improve the likelihood that each awardee will prceed to independent investigator status, and - in turn - these talented individuals will add dimension to the SARC Sarcoma SPORE.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ann Arbor
United States
Zip Code
Feng, Yong; Sassi, Slim; Shen, Jacson K et al. (2015) Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. J Orthop Res 33:199-207
Monument, Michael J; Johnson, Kirsten M; McIlvaine, Elizabeth et al. (2014) Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group. PLoS One 9:e104378
Choy, Edwin; Butrynski, James E; Harmon, David C et al. (2014) Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14:813
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Sankar, Savita; Theisen, Emily R; Bearss, Jared et al. (2014) Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res 20:4584-97
Zhang, Pingyu; Garnett, Jeannine; Creighton, Chad J et al. (2014) EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol 232:308-18
Sioletic, Stefano; Czaplinski, Jeffrey; Hu, Lan et al. (2014) c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol 234:190-202
Chen, Eleanor Y; DeRan, Michael T; Ignatius, Myron S et al. (2014) Glycogen synthase kinase 3 inhibitors induce the canonical WNT/?-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A 111:5349-54
Krook, Melanie A; Nicholls, Lauren A; Scannell, Christopher A et al. (2014) Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma. Mol Cancer Res 12:953-64
Jia, Bin; Choy, Edwin; Cote, Gregory et al. (2014) Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer Lett 342:104-12

Showing the most recent 10 out of 13 publications